Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'tirapazamine' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 104 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Williams, KJ; Cowen, RL; Stratford, IJ
      Hypoxia and oxidative stress in breast cancer - Tumour hypoxia - therapeutic considerations

      BREAST CANCER RESEARCH
    2. Tocher, JH
      Selective interaction of tirapazamine with DNA bases and DNA - A comparison of cyclic voltammetry and electrolysis techniques

      FREE RADICAL RESEARCH
    3. Thews, O; Kelleher, DK; Vaupel, P
      No improvement in perfusion and oxygenation of experimental tumors upon application of vasodilator drugs

      INTERNATIONAL JOURNAL OF ONCOLOGY
    4. Ganley, B; Chowdhury, G; Bhansali, J; Daniels, JS; Gates, KS
      Redox-activated, hypoxia-selective DNA cleavage by quinoxaline 1,4-di-N-oxide

      BIOORGANIC & MEDICINAL CHEMISTRY
    5. Hoff, PM; Saad, ED; Ravandi-Kashani, F; Czerny, E; Pazdur, R
      Phase I trial of i.v. administered tirapazamine plus cyclophosphamide

      ANTI-CANCER DRUGS
    6. Masunaga, S; Ono, K; Kirihata, M; Takagaki, M; Sakurai, Y; Kinashi, Y; Kobayashi, T; Nagasawa, H; Uto, Y; Hori, H
      Evaluation of the potential of p-boronophenylalaninol as a boron carrier in boron neutron capture therapy, referring to the effect on intratumor quiescent cells

      JAPANESE JOURNAL OF CANCER RESEARCH
    7. Zaffaroni, N; Fiorentini, G; De Giorgi, U
      Hyperthermia and hypoxia: new developments in anticancer chemotherapy

      EUROPEAN JOURNAL OF SURGICAL ONCOLOGY
    8. Brown, JM
      Therapeutic targets in radiotherapy

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    9. Shibamoto, Y; Zhou, L; Hatta, H; Mori, M; Nishimoto, S
      In vivo evaluation of a novel antitumor prodrug, 1-(2 '-oxopropyl)-5-fluorouracil (OFU001), which releases 5-fluorouracil upon hypoxic irradiation

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    10. Goldberg, Z; Evans, J; Birrell, G; Brown, JM
      An investigation of the molecular basis for the synergistic interaction oftirapazamine and cisplatin

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    11. Papadopoulou, MV; Ji, M; Bloomer, WD
      Schedule-dependent potentiation of chemotherapeutic drugs by the bioreductive compounds NLCQ-1 and tirapazamine against EMT6 tumors in mice

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    12. Cemazar, M; Parkins, CS; Holder, AL; Kranjc, S; Chaplin, DJ; Sersa, G
      Cytotoxicity of bioreductive drug tirapazamine is increased by applicationof electric pulses in SA-1 tumours in mice

      ANTICANCER RESEARCH
    13. Loadman, PM; Swaine, DJ; Bibby, MC; Welham, KJ; Patterson, LH
      A preclinical pharmacokinetic study of the bioreductive drug AQ4N

      DRUG METABOLISM AND DISPOSITION
    14. Blumenthal, RD; Taylor, A; Osorio, L; Ochakovskaya, R; Raleigh, JA; Papadopoulou, M; Bloomer, WD; Goldenberg, DM
      Optimizing the use of combined radioimmunotherapy and hypoxic cytotoxin therapy as a function of tumor hypoxia

      INTERNATIONAL JOURNAL OF CANCER
    15. Jounaidi, Y; Waxman, DJ
      Frequent, moderate-dose cyclophosphamide administration improves the efficacy of cytochrome P-450/cytochrome P-450 reductase-based cancer gene therapy

      CANCER RESEARCH
    16. Wouters, BG; Delahoussaye, YM; Evans, JW; Birrell, GW; Dorie, MJ; Wang, JL; MacDermed, D; Chiu, RK; Brown, JM
      Mitochondrial dysfunction after aerobic exposure to the hypoxic cytotoxin tirapazamine

      CANCER RESEARCH
    17. Gallagher, R; Hughes, CM; Murray, MM; Friery, OP; Patterson, LH; Hirst, DG; McKeown, SR
      The chemopotentiation of cisplatin by the novel bioreductive drug AQ4N

      BRITISH JOURNAL OF CANCER
    18. Delahoussaye, YM; Evans, JW; Brown, JM
      Metabolism of tirapazamine by multiple reductases in the nucleus

      BIOCHEMICAL PHARMACOLOGY
    19. Brown, JM
      Exploiting the hypoxic cancer cell: mechanisms and therapeutic strategies

      MOLECULAR MEDICINE TODAY
    20. Denny, WA; Wilson, WR
      Tirapazamine: a bioreductive anticancer drug that exploits tumour hypoxia

      EXPERT OPINION ON INVESTIGATIONAL DRUGS
    21. Papadopoulou, MV; Ji, M; Rao, MK; Bloomer, WD
      4-[3-(2-nitro-1-imidazolyl)propylamino]-7-chloroquinoline hydrochloride (NLCQ-1), a novel bioreductive agent as radiosensitizer in vitro and in vivo:Comparison with tirapazamine

      ONCOLOGY RESEARCH
    22. Wu, JH; Reynolds, CA
      Cyclophosphamides as hypoxia-activated diffusible cytotoxins: A theoretical study

      JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN
    23. Masunaga, S; Ono, K; Suzuki, M; Kinashi, Y; Takagaki, M; Kasai, S; Nagasawa, H; Uto, Y; Hori, H
      Changes in the sensitivity of intratumor cells during fractionated tirapazamine administration

      JAPANESE JOURNAL OF CANCER RESEARCH
    24. Masunaga, S; Ono, K; Suzuki, M; Kinashi, Y; Takagaki, M; Hori, H; Kasai, S; Nagasawa, H; Uto, Y
      Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: Reference to the effect on intratumor quiescent cells

      JAPANESE JOURNAL OF CANCER RESEARCH
    25. Craighead, PS; Pearcey, R; Stuart, G
      A phase I/II evaluation of tirapazamine administered intravenously concurrent with cisplatin and radiotherapy in women with locally advanced cervicalcancer

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    26. Masunaga, S; Ono, K; Nishimura, Y; Kanamori, S; Saga, T; Suzuki, M; Kinashi, Y; Takagaki, M; Kasal, S; Eng, D; Nagasawa, H; Uto, Y; Hori, H
      Combined effects of tirapazamine and mild hyperthermia on anti-angiogenic agent (TNP-470) treated tumors - Reference to the effect on intratumor quiescent cells

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    27. Stevens, CW; Lee, JS; Cox, J; Komaki, R
      Novel approaches to locally advanced unresectable non-small cell lung cancer

      RADIOTHERAPY AND ONCOLOGY
    28. Lee, AE; Wilson, WR
      Hypoxia-dependent retinal toxicity of bioreductive anticancer prodrugs in mice

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    29. Sharp, SY; Kelland, LR; Valenti, MR; Brunton, LA; Hobbs, S; Workman, P
      Establishment of an isogenic human colon tumor model for NQO1 gene expression: Application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo

      MOLECULAR PHARMACOLOGY
    30. Skalova, L; Nobilis, M; Szotakova, B; Wsol, V; Kubicek, V; Baliharova, V; Kvasnickova, E
      Effect of substituents on microsomal reduction of benzo(c)fluorene N-oxides

      CHEMICO-BIOLOGICAL INTERACTIONS
    31. Jounaidi, Y; Waxman, DJ
      Combination of the bioreductive drug tirapazamine with the chemotherapeutic prodrug cyclophosphamide for P450/P450-reductase-based cancer gene therapy

      CANCER RESEARCH
    32. Patterson, LH; McKeown, SR
      AQ4N: a new approach to hypoxia-activated cancer chemotherapy

      BRITISH JOURNAL OF CANCER
    33. Friery, OP; Gallagher, R; Murray, MM; Hughes, CM; Galligan, ES; McIntyre, IA; Patterson, LH; Hirst, DG; McKeown, SR
      Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine

      BRITISH JOURNAL OF CANCER
    34. Saunders, MP; Patterson, AV; Chinje, EC; Harris, AL; Stratford, IJ
      NADPH : cytochrome C (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line

      BRITISH JOURNAL OF CANCER
    35. Patterson, LH; McKeown, SR; Ruparella, K; Double, JA; Bibby, MC; Cole, S; Stratford, IJ
      Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent

      BRITISH JOURNAL OF CANCER
    36. Patterson, LH; Taiwo, FA
      Electron paramagnetic resonance spectrometry evidence for bioreduction of tirapazamine to oxidising free radicals under anaerobic conditions

      BIOCHEMICAL PHARMACOLOGY
    37. Yuan, X; Tabassi, K; Williams, JA
      Implantable polymers for tirapazamine treatments of experimental intracranial malignant glioma

      RADIATION ONCOLOGY INVESTIGATIONS
    38. El-Said, A; Menke, D; Dorie, MJ; Brown, JM
      Comparison of the effectiveness of tirapazamine and carbogen with nicotinamide in enhancing the response of a human tumor xenograft to fractionated irradiation

      RADIATION ONCOLOGY INVESTIGATIONS
    39. Bedikian, AY; Legha, SS; Eton, O; Buzaid, AC; Papadopoulos, N; Plager, C; McIntyre, S; Viallet, J
      Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma

      ANTI-CANCER DRUGS
    40. Wouters, BG; Wang, LH; Brown, JM
      Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer

      ANNALS OF ONCOLOGY
    41. Fuchs, T; Gates, KS; Hwang, JT; Greenberg, MM
      Photosensitization of guanine-specific DNA damage by a cyano-substituted quinoxaline di-N-oxide

      CHEMICAL RESEARCH IN TOXICOLOGY
    42. Shulman, LN; Buswell, L; Riese, N; Doherty, N; Loeffler, JS; von Roemeling, RW; Coleman, CN
      Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors

      INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
    43. Weitman, S; Mangold, G; Marty, J; Dexter, D; Hilsenbeck, S; Rake, J; Juniewicz, P; Von Hoff, D
      Evidence of enhanced in vivo activity using tirapazamine with paclitaxel and paraplatin regimens against the MV-522 human lung cancer xenograft

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    44. Masunaga, S; Ono, K; Hori, H; Kinashi, Y; Suzuki, M; Takagaki, M; Kasai, S; Nagasawa, H; Uto, Y
      Modification of tirapazamine-induced cytotoxicity in combination with mildhyperthermia and/or nicotinamide: reference to effect on quiescent tumour cells

      INTERNATIONAL JOURNAL OF HYPERTHERMIA
    45. Kwon, CH
      Metabolism-based anticancer drug design

      ARCHIVES OF PHARMACAL RESEARCH
    46. Yapp, DTT; Lloyd, DK; Zhu, JL; Lehnert, S
      Radiosensitization of a mouse tumor model by sustained intra-tumoral release of Etanidazole and Tirapazamine using a biodegradable polymer implant device

      RADIOTHERAPY AND ONCOLOGY
    47. Posakony, JJ; Pratt, RC; Rettig, SJ; James, BR; Skov, KA
      Porphyrins incorporating heterocyclic N-oxides: (oxidopyridyl)porphyrins, porphyrin-N-oxides, and a tirapazamine-porphyrin conjugate

      CANADIAN JOURNAL OF CHEMISTRY-REVUE CANADIENNE DE CHIMIE
    48. Chinje, EC; Patterson, AV; Saunders, MP; Lockyer, SD; Harris, AL; Stratford, IJ
      Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?

      BRITISH JOURNAL OF CANCER
    49. Kovacs, MS; Hocking, DJ; Evans, JW; Slim, BG; Wouters, BG; Brown, JM
      Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin

      BRITISH JOURNAL OF CANCER
    50. Phillips, RM
      Inhibition of DT-diaphorase (NAD(P)H : quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid(FAA): Implications for bioreductive drug development

      BIOCHEMICAL PHARMACOLOGY
    51. McLaughlin, KJ; Faibushevich, AA; Lunte, CE
      Microdialysis sampling with on-line microbore HPLC for the determination of tirapazamine and its reduced metabolites in rats

      ANALYST
    52. Lombard-Bohas, C; Cottu, PH; Dumortier, J; Marty, M; Mornex, F
      Chemoradiation: which new drugs can be combined with radiotherapy?

      CONCOMITANT CHEMORADIATION: CURRENT STATUS AND FUTURE
    53. CURRAN WJ
      RADIATION-INDUCED TOXICITIES - THE ROLE OF RADIOPROTECTANTS

      Seminars in radiation oncology
    54. Zhang, M; Stevens, G
      Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines

      MELANOMA RESEARCH
    55. PRAGER TC; KELLAWAY J; ZOU YL; URSO RG; MCINTYRE S; BEDIKIAN AY
      EVALUATION OF OCULAR SAFETY - TIRAPAZAMINE PLUS CISPLATIN IN PATIENTSWITH METASTATIC MELANOMAS

      Anti-cancer drugs
    56. MASUNAGA S; ONO K; SAKURAI Y; HORI H; KOBAYASHI T; TAKAGAKI M; SUZUKI M; KINASHI Y; AKABOSHI M
      APPLICABILITY OF COMBINATION WITH TIRAPAZAMINE IN BORON NEUTRON-CAPTURE THERAPY

      Japanese journal of cancer research
    57. LEE DJ; TROTTI A; SPENCER S; ROSTOCK R; FISHER C; VONROEMELING R; HARVEY E; GROVES EG
      CONCURRENT TIRAPAZAMINE AND RADIOTHERAPY FOR ADVANCED HEAD AND NECK CARCINOMAS - A PHASE-II STUDY

      International journal of radiation oncology, biology, physics
    58. WILSON WR; LI AE; COWAN DSM; SIIM BG
      ENHANCEMENT OF TUMOR RADIATION RESPONSE BY THE ANTIVASCULAR AGENT 5,6-DIMETHYLXANTHENONE-4-ACETIC ACID

      International journal of radiation oncology, biology, physics
    59. HICKS KO; FLEMING Y; SIIM BG; KOCH CJ; WILSON WR
      EXTRAVASCULAR DIFFUSION OF TIRAPAZAMINE - EFFECT OF METABOLIC CONSUMPTION ASSESSED USING THE MULTICELLULAR LAYER MODEL

      International journal of radiation oncology, biology, physics
    60. Kyle, AH; Minchinton, AI
      Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    61. Brown, JM; Wang, LH
      Tirapazamine: laboratory data relevant to clinical activity

      ANTI-CANCER DRUG DESIGN
    62. Patterson, AV; Saunders, MP; Chinje, EC; Patterson, LH; Stratford, IJ
      Enzymology of tirapazamine metabolism: a review

      ANTI-CANCER DRUG DESIGN
    63. Kelson, AB; McNamara, JP; Pandey, A; Ryan, KJ; Dorie, MJ; McAfee, PA; Menke, DR; Brown, JM; Tracy, M
      1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxinswith antitumor activity

      ANTI-CANCER DRUG DESIGN
    64. SIEMANN DW; HINCHMAN CA
      POTENTIATION OF CISPLATIN ACTIVITY BY THE BIOREDUCTIVE AGENT TIRAPAZAMINE

      Radiotherapy and oncology
    65. LIN PS; HO KC
      CUTIRA BRACHYTHERAPY - A NEW COMBINATION OF RADIOACTIVE COPPER ISOTOPES AND THE HYPOXIC CYTOTOXIN, TIRAPAZAMINE, FOR TARGETED TUMOR-THERAPY

      The Journal of nuclear medicine
    66. PHILLIPS RM; LOADMAN PM; CRONIN BP
      EVALUATION OF A NOVEL IN-VITRO ASSAY FOR ASSESSING DRUG PENETRATION INTO AVASCULAR REGIONS OF TUMORS

      British Journal of Cancer
    67. BROWN JM
      EXPLOITING TUMOR HYPOXIA AND OVERCOMING MUTANT P53 WITH TIRAPAZAMINE

      British Journal of Cancer
    68. GATZEMEIER U; RODRIGUEZ G; TREAT J; MILLER V; VONROEMELING R; VIALLET J; REY A
      TIRAPAZAMINE-CISPLATIN - THE SYNERGY

      British Journal of Cancer
    69. BOYER MJ
      BIOREDUCTIVE AGENTS - A CLINICAL UPDATE

      Oncology research
    70. BEDIKIAN AY; LEGHA SS; ETON O; BUZAID AC; PAPADOPOULOS N; COATES S; SIMMONS T; NEEFE J; VONROEMELING R
      PHASE-II TRIAL OF TIRAPAZAMINE COMBINED WITH CISPLATIN IN CHEMOTHERAPY OF ADVANCED MALIGNANT-MELANOMA

      Annals of oncology
    71. MILLER VA; NG KK; GRANT SC; KINDLER H; PIZZO B; HEELAN RT; VONROEMELING R; KRIS MG
      PHASE-II STUDY OF THE COMBINATION OF THE NOVEL BIOREDUCTIVE AGENT, TIRAPAZAMINE, WITH CISPLATIN IN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG-CANCER

      Annals of oncology
    72. MASUNAGA S; ONO K; HORI H; SHIBATA T; SUZUKI M; KINASHI Y; TAKAGAKI M; AKABOSHI M
      EFFECTS OF BIOREDUCTIVE AGENTS, TIRAPAZAMINE AND MITOMYCIN-C, ON QUIESCENT CELL-POPULATIONS IN SOLID TUMORS, EVALUATED BY MICRONUCLEUS ASSAY

      Japanese journal of cancer research
    73. GRAHAM MA; SENAN S; ROBIN H; ECKHARDT N; LENDREM D; HINCKS J; GREENSLADE D; RAMPLING R; KAYE SB; VONROEMELING R; WORKMAN P
      PHARMACOKINETICS OF THE HYPOXIC CELL CYTOTOXIC AGENT TIRAPAZAMINE ANDITS MAJOR BIOREDUCTIVE METABOLITES IN MICE AND HUMANS - RETROSPECTIVEANALYSIS OF A PHARMACOKINETICALLY GUIDED DOSE-ESCALATION STRATEGY IN A PHASE-I TRIAL

      Cancer chemotherapy and pharmacology
    74. DORIE MJ; BROWN JM
      MODIFICATION OF THE ANTITUMOR-ACTIVITY OF CHEMOTHERAPEUTIC DRUGS BY THE HYPOXIC CYTOTOXIC AGENT TIRAPAZAMINE

      Cancer chemotherapy and pharmacology
    75. OLIVE PL; BANATH JP; DURAND RE
      DETECTION OF SUBPOPULATIONS RESISTANT TO DNA-DAMAGING AGENTS IN SPHEROIDS AND MURINE TUMORS

      Mutation research
    76. SIIM BG; MENKE DR; DORIE MJ; BROWN JM
      TIRAPAZAMINE-INDUCED CYTOTOXICITY AND DNA-DAMAGE IN TRANSPLANTED TUMORS - RELATIONSHIP TO TUMOR HYPOXIA

      Cancer research
    77. PATTERSON AV; SAUNDERS MP; CHINJE EC; TALBOT DC; HARRIS AL; STRATFORD IJ
      OVEREXPRESSION OF HUMAN NADPH-CYTOCHROME-C (P450) REDUCTASE CONFERS ENHANCED SENSITIVITY TO BOTH TIRAPAZAMINE (SR 4233) AND RSU 1069

      British Journal of Cancer
    78. ELWELL JH; SIIM BG; EVANS JW; BROWN JM
      ADAPTATION OF HUMAN TUMOR-CELLS TO TIRAPAZAMINE UNDER AEROBIC CONDITIONS - IMPLICATIONS OF INCREASED ANTIOXIDANT ENZYME-ACTIVITY TO MECHANISM OF AEROBIC CYTOTOXICITY

      Biochemical pharmacology
    79. GILBERT MS; RUPNOW BA; RAMIREZ DA; TRISLER KD; KNOX SJ
      OVER-EXPRESSION OF BCL-2 PROTECTS AGAINST APOPTOSIS INDUCED BY THE BIOREDUCTIVE CYTOTOXIC DRUG SR4233 (TIRAPAZAMINE)

      Cell death and differentiation
    80. PRIYADARSINI KI; TRACY M; WARDMAN P
      THE ONE-ELECTRON REDUCTION POTENTIAL OF 3-AMINO-1,2,4-BENZOTRIAZINE 1,4-DIOXIDE (TIRAPAZAMINE) - A HYPOXIA-SELECTIVE BIOREDUCTIVE DRUG

      Free radical research
    81. SHIBATA T; SHIBAMOTO Y; SASAI K; OYA N; MURATA R; TAKAGI T; HIRAOKA M; ABE M
      COMPARISON OF IN-VIVO EFFICACY OF HYPOXIC CYTOTOXIN TIRAPAZAMINE AND HYPOXIC CELL RADIOSENSITIZER KU-2285 IN COMBINATION WITH SINGLE AND FRACTIONATED-IRRADIATION

      Japanese journal of cancer research
    82. LIN PS; HO KC; YANG SJ
      TIRAPAZAMINE (SR-4233) INTERRUPTS CELL-CYCLE PROGRESSION AND INDUCES APOPTOSIS

      Cancer letters
    83. HENDERSON ND; PLUMB JA; ROBINS DJ; WORKMAN P
      SYNTHESIS AND ANTICANCER ACTIVITY OF 2,6-DISUBSTITUTED N-METHYLPIPERIDINE DERIVATIVES AND THEIR N-OXIDES

      Anti-cancer drug design
    84. STERN S; GUICHARD M
      EFFICACY OF AGENTS COUNTERACTING HYPOXIA IN FRACTIONATED RADIATION REGIMES

      Radiotherapy and oncology
    85. CRESPO FJM; PALOP JA; SAINZ Y; NARRO S; SENADOR V; GONZALEZ M; DECERAIN AL; MONGE A; HAMILTON E; BARKER AJ
      4-CYANO-2-OXO-1,2,4-OXADIAZOLO[2,3-A]QUINOXALINE 5-N-OXIDES - NEW SYNTHETIC METHOD AND REACTION WITH ALCOHOLS - POTENTIAL CYTOTOXIC ACTIVITY

      Journal of heterocyclic chemistry
    86. ROSS D; BEALL HD; SIEGEL D; TRAVER RD; GUSTAFSON DL
      ENZYMOLOGY OF BIOREDUCTIVE DRUG ACTIVATION

      British Journal of Cancer
    87. MCKEOWN SR; FRIERY OP; MCINTYRE IA; HEJMADI MV; PATTERSON LH; HIRST DG
      EVIDENCE FOR A THERAPEUTIC GAIN WHEN AQ4N OR TIRAPAZAMINE IS COMBINEDWITH RADIATION

      British Journal of Cancer
    88. SHIBATA T; SHIBAMOTO Y; SASAI K; OYA N; MURATA R; TAKAGI T; HIRAOKA M; TAKAHASHI M; ABE M
      TIRAPAZAMINE - HYPOXIC CYTOTOXICITY AND INTERACTION WITH RADIATION ASASSESSED BY THE MICRONUCLEUS ASSAY

      British Journal of Cancer
    89. WARDMAN P; PRIYADARSINI KI; DENNIS MF; EVERETT SA; NAYLOR MA; PATEL KB; STRATFORD IJ; STRATFORD MRL; TRACY M
      CHEMICAL-PROPERTIES WHICH CONTROL SELECTIVITY AND EFFICACY OF AROMATIC N-OXIDE BIOREDUCTIVE DRUGS

      British Journal of Cancer
    90. CHAPLIN DJ; PETTIT GR; PARKINS CS; HILL SA
      ANTIVASCULAR APPROACHES TO SOLID TUMOR-THERAPY - EVALUATION OF TUBULIN BINDING-AGENTS

      British Journal of Cancer
    91. SIIM BG; VANZIJL PL; BROWN JM
      TIRAPAZAMINE-INDUCED DNA-DAMAGE MEASURED USING THE COMET ASSAY CORRELATES WITH CYTOTOXICITY TOWARDS HYPOXIC TUMOR-CELLS IN-VITRO

      British Journal of Cancer
    92. LARTIGAU E; GUICHARD M
      THE EFFECT OF TIRAPAZAMINE (SR-4233) ALONE OR COMBINED WITH CHEMOTHERAPEUTIC-AGENTS ON XENOGRAFTED HUMAN TUMORS

      British Journal of Cancer
    93. HOLDEN SA; TEICHER BA
      COMBINATIONS OF TNP-470 OR SR-4233 WITH ANTITUMOR ALKYLATING-AGENTS IN EMT-6 SPHEROIDS AND MONOLAYERS

      International journal of oncology
    94. ROBIN H; SENAN S; WORKMAN P; GRAHAM MA
      DEVELOPMENT AND VALIDATION OF A SENSITIVE SOLID-PHASE-EXTRACTION AND HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY ASSAY FOR THE BIOREDUCTIVE AGENT TIRAPAZAMINE AND ITS MAJOR METABOLITES IN MOUSE AND HUMAN PLASMA FORPHARMACOKINETICALLY GUIDED DOSE-ESCALATION

      Cancer chemotherapy and pharmacology
    95. SHIBATA T; SHIBAMOTO Y; SASAI K; OYA N; TAKAGI T; MURATA R; ABE M
      ASSESSMENT OF MICRONUCLEUS INDUCTION IN SCCVII CELLS TREATED WITH BIOREDUCTIVE AGENTS, WIN-59075 (SR-4233) AND MITOMYCIN-C, UNDER AEROBIC AND HYPOXIC CONDITIONS

      Mutation research. Genetic toxicology testing
    96. PATTERSON AV; BARHAM HM; CHINJE EC; ADAMS GE; HARRIS AL; STRATFORD IJ
      IMPORTANCE OF P450 REDUCTASE-ACTIVITY IN DETERMINING SENSITIVITY OF BREAST-TUMOR CELLS TO THE BIOREDUCTIVE DRUG, TIRAPAZAMINE (SR-4233)

      British Journal of Cancer
    97. KHAN S; OBRIEN PJ
      MOLECULAR MECHANISMS OF TIRAPAZAMINE (SR-4233, WIN-59075)-INDUCED HEPATOCYTE TOXICITY UNDER LOW-OXYGEN CONCENTRATIONS

      British Journal of Cancer
    98. TOCHER JH; EDWARDS DI
      ELECTROCHEMICAL STUDIES OF TIRAPAZAMINE - GENERATION OF THE ONE-ELECTRON REDUCTION PRODUCT

      Free radical research
    99. RAMPLING R; CRUICKSHANK G; LEWIS AD; FITZSIMMONS SA; WORKMAN P
      DIRECT MEASUREMENT OF PO2 DISTRIBUTION AND BIOREDUCTIVE ENZYMES IN HUMAN-MALIGNANT BRAIN-TUMORS

      International journal of radiation oncology, biology, physics
    100. KIM IH; BROWN JM
      REOXYGENATION AND REHYPOXIATION IN THE SCCVII MOUSE-TUMOR

      International journal of radiation oncology, biology, physics


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 28/10/20 alle ore 21:15:23